TABLE 10.

Activity of samatasvir against genotype 1a replicons bearing amino acid substitutions in NS3, NS4B, and NS5A

Region	Substitution	Mean fold change ± SD witha:			Replicative capacity (% of WT ± SD)a
		Samatasvir	Daclatasvir	IDX184
NS3	T260A	1.6 ± 0.3	1.7 ± 0.3	1.7 ± 0.2	300 ± 140
NS4B	E15G	1.5 ± 0.1	1.6 ± 0.2	1.6 ± 0.1	264 ± 18
NS5A	K24E	1.8 ± 0.5	1.8 ± 0.4	1.6 ± 0.2	79 ± 25
	M28T	150 ± 10	170 ± 20	1.06 ± 0.14	66 ± 7
	Q30E	420 ± 80	2,900 ± 400	1.11 ± 0.14	119 ± 7
	Q30H	24 ± 2	150 ± 30	1.07 ± 0.10	100 ± 2
	Q30K	310 ± 100	750 ± 190	0.89 ± 0.17	100 ± 14
	Q30R	10 ± 1	95 ± 22	1.04 ± 0.07	119 ± 7
	L31F	68 ± 14	43 ± 9	1.06 ± 0.31	85 ± 4
	L31M	310 ± 60	110 ± 30	1.04 ± 0.21	143 ± 32
	L31V	420 ± 80	900 ± 180	1.33 ± 0.10	210 ± 8
	P32L	170 ± 10	140 ± 20	0.89 ± 0.04	16 ± 3
	Y93C	40 ± 5	290 ± 50	1.06 ± 0.16	92 ± 18
	Y93H	4,400 ± 900	1,400 ± 500	1.05 ± 0.25	43 ± 4
	Y93N	14,000 ± 3,000	7,800 ± 3,500	1.01 ± 0.25	60 ± 6
	E295G	1.6 ± 0.2	1.6 ± 0.2	1.3 ± 0.1	132 ± 36
	R318W (GT 1a)b	RDc	RD	RD	1.8 ± 0.8
	R318W (GT 1b)d	1.7 ± 0.6	1.0 ± 0.1	0.75 ± 0.23	79 ± 4

^an = 3. WT, wild type.

^bNS5A R318W substitution in the genotype 1a replicon.

^cRD, replication deficient.

^dNS5A R318W substitution in the genotype 1b replicon.